
Relia Tech/兔抗人B7-H1/PD-L1/100µg/102-P23
市场价:
¥4700.00
美元价:
2820.00
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Cat-Nr. | 102-P23 |
Size | 100 µg |
Price | 235 € |
Category | Polyclonal Antibody |
Clone Nr. | Rabbit IgG |
Species Reactivity | Human |
Formulation | lyophilized from PBS |
Buffer | PBS |
Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
Stability and Storage | The lyophilized antibody is stable for at least 2 years from date of receipt at -20°C. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C. |
Preparation | Produced from sera of rabbits immunized with highly pure recombinant Human B7-H1/PD-L1 Fc. Anti-Human B7-H1-specific antibody was purified by affinity chromatography employing an immobilized Human B7-H1/PD-L1 Fc matrix. |
Antigen | Recombinant human B7-H1/PD-L1 Fc |
Application | ELISA, WB |
Synonyms | Programmed Death Ligand 1, Programmed cell death 1 Ligand 1 (PDCD1L1), PD-1, B7-H1 (B7 homolog 1), CD274, SLEB2, SLE1 |
Description | Human B7 homolog 1 (B7H1), also called programmed death ligand 1 (PDL1) and programmed cell death 1 ligand 1 (PDCD1L1), is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. Other family members include B71, B72, B7H2, PDL2 and B7H3. B7 proteins are members of the immunoglobulin (Ig) superfamily, their extracellular domains contain 2 Ig-like domains and all members have short cytoplasmic domains. Among the family members, they share about 20 25% amino acid identity. Human and mouse B7H1 share approximately 70% amino acid sequence identity. B7H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. The B7H1 gene encodes a 290 amino acid (aa) type I membrane precursor protein with a putative 18 aa signal peptide, a 221 aa extracellular domain, a 21 aa transmembrane region, and a 31 aa cytoplasmic domain. Human B7H1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. B7H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. B7H1 expression is also induced in dendritic cells and keratinocytes after IFNγ stimulation. Interaction of B7H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7H1: PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
Uniprot ID | Q9NZQ7 |
Protein RefSeq | NP_054862.1 |
mRNA RefSeq | NM_014143.3 |
品牌介绍
Receptor Ligand Technologies GmbH 公司(RELIA Tech )位于德国不伦瑞克,是一家后基因组生物技术公司,该公司运用独特的技术专注于受体和配体的发现与研究,从而使商业化,产品广泛使用于科学研究,实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子,生长因子,重组蛋白产品一致内毒素检测项目,且内毒素水平非常低。 受体配体技术有限公司(RELIATech)是一家后基因组生物技术公司,致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化,用于研究,诊断和临床领域。该公司位于德国不伦瑞克,由以下公司成立于2000年10月: 阿夫纳·亚永教授以色列魏兹曼科学研究所(WIS) 赫伯特·韦奇博士德国生物技术德国研究中心(GBF) Bernhard Barleon博士德国肿瘤生物学诊所(KTB) 创始人是从事细胞生长因子相互作用,酪氨酸激酶及其信号传导途径(涉及组织重塑,体内平衡和疾病)领域的细胞和分子生物学家,工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成,肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白,连同其跨膜/“可溶性受体”和相关的激酶,在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化,组织重塑和体内平衡,并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现,以及对它们功能的阐明,无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品,用于基础研究,药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们